My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

126.52 -0.66 (-0.52%)

Streaming Delayed Price Updated: 2:54 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

68 69 Next >

5 Reasons Gilead Sciences is a Better Buy Than You Think

October 10, 2023

Gilead Sciences is a value and high-yielding stock on the brink of a stock rebound that could add double-digits to investors portfolios this year an next.

Via MarketBeat

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip ↗

October 10, 2023

Wall Street price targets suggest this stock can rocket more than 400% higher.

Via The Motley Fool

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

October 05, 2023

Via Benzinga

5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio

October 05, 2023

Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps

Via MarketBeat

Topics Economy Stocks

How Is The Market Feeling About Gilead Sciences? ↗

September 21, 2023

Via Benzinga

Gilead Sciences Unusual Options Activity ↗

September 20, 2023

Via Benzinga

Pharma Giants Combine Forces to Fight New M&A Rules ↗

October 04, 2023

Some of pharma's biggest players — including Merck, Amgen, Abbvie, and Gilead — formed an alliance to fight looming M&A reforms.

Via The Motley Fool

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023

October 03, 2023

From Gilead Sciences, Inc.

Via Business Wire

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs ↗

October 02, 2023

CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.

Via InvestorPlace

Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders

October 02, 2023

From Gilead Sciences, Inc.

Via Business Wire

$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗

September 18, 2023

Via Benzinga

3 Magnificent Dividend Stocks to Buy in October ↗

September 30, 2023

These stocks come with great dividends and more.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2023

Via Benzinga

Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study ↗

September 28, 2023

Gilead Sciences Inc (NASDAQ: GILD) said it has

Via Benzinga

Gilead Sciences Adapts to Economic Shifts to Support Investor Confidence ↗

September 28, 2023

By the end of today, September 28, 2023, Gilead Sciences (NASDAQ:GILD) is set to deliver a dividend payout of $0.75 per share, equating to an annualized dividend yield of 3.96%.

Via Benzinga

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗

September 27, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session

September 26, 2023

Via Investor Brand Network

3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗

September 21, 2023

Many stocks have nosebleed valuations. But not these.

Via The Motley Fool

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment

September 19, 2023

From Gilead Sciences, Inc.

Via Business Wire

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗

September 19, 2023

Good medicines aren't always good business.

Via The Motley Fool

Can These 3 Healthcare Dividend Stocks Deliver Income Growth?

September 18, 2023

Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.

Via MarketBeat

Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

September 18, 2023

From Gilead Sciences, Inc.

Via Business Wire

Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

September 13, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food...

Via FinancialNewsMedia

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

Via Talk Markets

Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment ↗

September 11, 2023

Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy.

Via Benzinga

Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

September 10, 2023

From Gilead Sciences, Inc.

Via Business Wire

What You Need to Know About Hepatitis C This Recovery Month

September 08, 2023

(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are...

Via Brandpoint

How To Earn $500 A Month From Gilead Sciences Stock ↗

September 08, 2023

Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock.

Via Benzinga

Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades ↗

September 08, 2023

BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.